-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the journal CLINICAL CANCER RESEARCH published the results of a post-hoc analysis of a phase III clinical study CATNON (NCT00626990), which mainly evaluated whether the addition of temozolomide to radiotherapy in IDH wild-type glioblastoma improved patients.
's curative effect
.
's curative effect
.
The main purpose is to evaluate whether adding temozolomide to radiotherapy in IDH wild-type glioblastoma improves the patient's efficacy
Of the 751 patients enrolled in the CATNON study, 670 had fully molecularly characterized tumors
.
Of these, 159 met the WHO 2021 IDH molecular criteria for wild-type glioblastoma
Of the 751 patients enrolled in the CATNON study, 670 had fully molecularly characterized tumors
Median overall survival (OS) was 1.
Among the 152 patients, 53 (34.
9%) were MGMT promoter methylated, and 99 (65.
1%) were MGMT unmethylated
.
Patients with MGMT-methylated tumors had better overall survival than non-methylated patients (HR=0.
Among the 152 patients, 53 (34.
Likewise, the addition of temozolomide was not detected in both the MGMT promoter methylated tumor group (HR 1.
36, 95% CI 0.
75-2.
48) and the MGMT unmethylated tumor group (HR 0.
88, 95% CI 0.
54-1.
42) Survival benefit
.
36, 95% CI 0.
75-2.
48) and the MGMT unmethylated tumor group (HR 0.
88, 95% CI 0.
54-1.
42) Survival benefit
.
Likewise, the addition of temozolomide was not detected in both the MGMT promoter methylated tumor group (HR 1.
In adjusted multivariate analysis, the addition of temozolomide did not improve overall survival (HR=1.
03, 95% CI 0.
69-1.
53) and progression-free survival (HR=0.
79, 95% CI 0.
55-1.
13) compared with radiotherapy alone
.
03, 95% CI 0.
69-1.
53) and progression-free survival (HR=0.
79, 95% CI 0.
55-1.
13) compared with radiotherapy alone
.
In adjusted multivariate analysis, the addition of temozolomide did not improve overall survival (HR=1.
Taken together, the study showed that in IDH wild-type glioblastoma, the addition of temozolomide to radiotherapy did not improve patient outcomes
.
.
Studies have shown that in IDH wild-type glioblastoma, the addition of temozolomide to radiotherapy does not improve patient outcomes
Original source:
Original source:Tesileanu CMS, Sanson M, Wick W, Brandes AA, et al .
Tesileanu CMS, Sanson M, Wick W, Brandes AA, et al .
Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post-hoc analysis of the EORTC randomized phase 3 CATNON trial.
Clin Cancer Res.
2022 Mar 11 :clincanres.
4283.
2021.
doi: 10.
1158/1078-0432.
CCR-21-4283.
Epub ahead of print.
PMID: 35275197.
Tesileanu CMS, Sanson M, Wick W, Brandes AA, et al .
Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post-hoc analysis of the EORTC randomized phase 3 CATNON trial.
Clin Cancer Res.
2022 Mar 11:clincanres.
4283.
2021.
doi: 10.
1158/1078-0432.
CCR-21-4283.
Epub ahead of print.
PMID: 35275197.
Leave a message here
